NS Pharma`s Duchenne drug Viltepso flunks confirmatory trial
PARAMUS, N.J., May 27, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd., announced today that it has received preliminary analysis results from the global Phase 3 clinical trial (RACER53 study, NCT04060199) of NS-065/NCNP-01 (generic name: viltolarsen).
PARAMUS, N.J., April 4, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics – headquartered in London, United Kingdom, to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system. The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.
NS Pharma, Inc. has announced that its parent company, Nippon Shinyaku Co., headquartered in Kyoto, Japan, has entered into a joint research agreement with MiNA Therapeutics, headquartered in London, United Kingdom (UK), to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system. The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in the US.
NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Conference
PARAMUS, N.J., Jan. 22, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis (EGPA).
PARAMUS, N.J., Dec. 21, 2023 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd., announced that, on December 13, 2023, the European Commission (EC) has granted orphan drug designation for NS-089/NCNP-02, which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne), a rare and deadly genetic disorder that occurs primarily in males. There are various genetic mutations that cause Duchenne, and NS-089/NCNP-02 targets a gene mutation that can be treated by exon 44 skipping.
PARAMUS, N.J., Aug. 8, 2023 /PRNewswire/ -- NS Pharma, Inc. announced today that the European Commission (EC) has granted Orphan Drug Designation to NS-018 (ilginatinib) an oral, selective JAK2 inhibitor which is being investigated for the treatment of myelofibrosis (MF).
PARAMUS, N.J., Aug. 7, 2023 /PRNewswire/ -- NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.